Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GeneDx Holdings Corp.'s filings document financial results and operating disclosures for a genomics diagnostics company focused on rare disease testing. Form 8-K reports furnish quarterly and annual results, earnings presentations, preliminary revenue and testing-volume guidance, changes in statement presentation, and modifications to non-GAAP financial measure methodology.
The filing record also covers capital structure and governance matters, including a term loan agreement used to refinance existing debt, Class A common stock and Nasdaq-listed warrant disclosures, board composition changes, and definitive proxy materials. Proxy filings describe director elections, executive compensation, equity awards, stockholder voting matters, and related corporate governance policies.
GeneDx Holdings Corp. CEO Katherine Stueland exercised 80,000 restricted stock units into Class A common stock and had 46,933 shares sold to cover tax withholding obligations. The sales were executed as non-discretionary “sell to cover” transactions at weighted average prices between approximately $60.93 and $65.61 per share.
After these transactions, she beneficially owned 91,514 shares of Class A common stock and also held restricted stock units representing contingent rights to receive up to 334,695 additional shares, plus options to purchase up to 107,610 shares that vest according to their terms.
GeneDx Holdings Corp.'s chief executive officer Katherine Stueland reported routine equity compensation activity involving restricted stock units and related tax sales. She exercised RSUs covering 30,671 shares of Class A Common Stock at no cost as tranches vested on March 15–16. To cover tax withholding obligations from these vestings, she sold 17,179 shares in open-market transactions at weighted average prices in ranges around $75.74 to $78.16 per share pursuant to a sell-to-cover arrangement, which the filing notes was not a discretionary transaction. Following these tax-related sales, she directly owned 58,447 shares of Class A Common Stock and held RSUs representing up to 414,695 additional shares and options to purchase 107,610 shares, all vesting according to their existing terms.
GeneDx Holdings Corp. Chief Financial Officer Kevin Feeley reported routine equity compensation activity. On March 15–16, 2026, he exercised restricted stock units that converted into a total of 11,012 shares of Class A Common Stock at no cost.
On March 16, he then sold 5,706 shares of Class A Common Stock in multiple open-market transactions at weighted average prices in the mid‑$70s. According to the disclosure, these sales were made solely to cover tax withholding obligations under a “sell to cover” arrangement and were not discretionary.
After these transactions, Feeley beneficially owned 27,148 shares of Class A Common Stock and also held RSUs for up to 109,423 shares and options for up to 25,906 shares, all vesting according to their existing schedules.
GeneDx Holdings Corp. chief financial officer Kevin Feeley reported routine equity compensation activity. On March 9, 2026, he exercised restricted stock units for 2,462 shares of Class A common stock at no cost, converting RSUs into shares. He then sold 1,280 shares at a weighted average price of $86.754 per share in a "sell to cover" transaction to satisfy tax withholding obligations, which the footnotes state was not a discretionary trade. Following these moves, he directly owned 21,842 shares of Class A common stock and also held RSUs covering up to 120,435 additional shares and options for up to 25,906 shares, all vesting under their existing schedules.
GeneDx Holdings Corp. CEO Katherine Stueland reported routine equity compensation activity. She exercised restricted stock units into 6,546 shares of Class A Common Stock at no cost, then sold 3,678 of those shares at a weighted average price of $86.748 per share solely to cover tax withholding obligations via a “sell to cover” transaction, which the filing states was not discretionary.
After these transactions, she directly owned 44,955 shares of Class A Common Stock. The filing also notes additional unvested awards: RSUs representing contingent rights to receive up to 445,366 shares and options to purchase up to 107,610 shares, which vest over time according to their terms.
GeneDx Holdings Corp. chief financial officer Kevin Feeley acquired additional company stock in an insider transaction. On March 6, 2026, he obtained 1,986 shares of GeneDx Class A common stock directly from the company at $88.11 per share under a subscription agreement exempt under Rule 16b-3(d). After this award, his direct ownership increased to 20,660 shares of Class A common stock.
GeneDx Holdings Corp. reported that Chief Executive Officer Katherine Stueland acquired additional company stock. On March 6, 2026, she obtained 3,404 shares of GeneDx Class A common stock directly from the company in an exempt transaction at $88.11 per share, based on that day’s closing price.
Following this acquisition, Stueland directly holds 42,087 shares of GeneDx Class A common stock. The transaction was executed under a Subscription Agreement between GeneDx and Stueland and was structured to qualify for exemption under Rule 16b-3(d).
GeneDx Holdings Corp. reported that investment funds advised by Corvex Management LP, with Keith A. Meister as a control person, made open-market purchases of a total of 169,521 shares of Class A common stock on March 3 and March 5 at prices generally ranging from about $70 to $82 per share.
After these trades, investment funds advised by Corvex directly held 3,228,150 GeneDx Class A shares. CMLS Holdings LLC held 333,144 shares, over which Mr. Meister shares voting and investment discretion, and Mr. Meister’s beneficial holdings also include 20,129 shares issued upon vesting of restricted stock units for his board service. Corvex and Mr. Meister each disclaim beneficial ownership except to the extent of their pecuniary interest.
GeneDx Holdings Corp. reported that Chief Operating Officer Bryan Dechairo acquired 10,430 restricted stock units (RSUs) as an equity award. Each RSU represents a contingent right to receive one share of Class A common stock for no cash consideration upon settlement.
The award vests over time, with 25% of the RSUs vesting each year on the anniversary of the grant date. The first tranche is scheduled to vest on April 1, 2027, provided Dechairo continues to serve the company on each vesting date. The RSUs have no expiration; they either vest or are cancelled before vesting.
GeneDx Holdings Corp. Chief Financial Officer Kevin Feeley reported a mix of equity awards and share sales. On March 3, 2026, he acquired 15,262 shares of Class A Common Stock and 10,865 RSUs at no cost in connection with a performance-based restricted stock unit award tied to revenue and adjusted net income.
On March 4, 2026, he sold a total of 6,187 shares of Class A Common Stock in open-market transactions at weighted average prices in the high-$70 range to cover tax withholding obligations from that vesting. After these transactions, he beneficially owned 18,674 shares, plus RSUs for up to 122,897 shares and options for up to 25,906 shares, subject to vesting.